On the Record · Endo International
Endo International competitors, on the record
The companies Endo International itself names as competitors in its annual reports, 2021 to 2023, each with the sentence it appears in and the filing it came from.
Who Endo International names
| Company | Named in |
|---|---|
| Amgen, Inc. | 2023 |
| Amneal | 2023 |
| Aurobindo Pharma Limited | 2023 |
| Jazz Pharmaceuticals plc | 2023 |
| Sandoz | 2023 |
| Takeda Pharmaceutical Company Limited | 2023 |
| Teva Pharmaceutical Industries Limited | 2023 |
| Viatris Inc. | 2023 |
In its own words
Amgen, Inc., Jazz Pharmaceuticals plc, Takeda Pharmaceutical Company Limited, Viatris Inc.
Word for word“This segment’s major competitors, including Viatris Inc. (Viatris), Jazz Pharmaceuticals plc (Jazz), Takeda Pharmaceutical Company Limited and Amgen, Inc., among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.” 10-K for 2023
Amneal, Aurobindo Pharma Limited, Sandoz, Teva Pharmaceutical Industries Limited
Word for word“Our major competitors, including Teva Pharmaceutical Industries Limited, Viatris, Sandoz, Aurobindo Pharma Limited and Amneal, among others, vary by product.” 10-K for 2023
Read from Endo International’s annual reports (10-K for 2023, 10-K for 2022, 10-K for 2021) and the financial data it files with the SEC, as of 2024-03-06. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.